Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Not listed Phase 3 Interventional

RESULT: Reliable, Emergent Solution Using Liprotamase Treatment

ClinicalTrials.gov ID: NCT03051490

Public ClinicalTrials.gov record NCT03051490. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 2:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active-Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency

Study identification

NCT ID
NCT03051490
Recruitment status
Not listed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Anthera Pharmaceuticals
Industry
Enrollment
140 participants

Conditions and interventions

Interventions

  • Liprotamase Drug
  • porcine PERT Drug

Drug

Eligibility (public fields only)

Age range
7 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 27, 2017
Primary completion
Feb 27, 2018
Completion
May 31, 2018
Last update posted
Mar 7, 2018

2017 – 2018

United States locations

U.S. sites
28
U.S. states
19
U.S. cities
27
Facility City State ZIP Site status
Investigator Site 139 Little Rock Arkansas 72202
Investigator Site #123 Long Beach California 90806
Investigator Site 107 Los Angeles California 90033
Investigator Site 143 Orange California 92868
Investigator Site 150 Denver Colorado 80206
Investigator Site 147 Wilmington Delaware 19803
Investigator Site 117 Altamonte Springs Florida 32701
Investigator Site 102 Jacksonville Florida 32207
Investigator Site 130 Miami Florida 33136
Investigator Site 151 West Palm Beach Florida 33407
Investigator Site 110 Atlanta Georgia 30342
Investigator Site 109 Glenview Illinois 60025
Investigator Site 148 Iowa City Iowa 52242
Investigator Site #122 Louisville Kentucky 40202
Investigator Site 132 Portland Maine 04102
Investigator Site 124 Ann Arbor Michigan 48109
Investigator Site 140 Kalamazoo Michigan 49008
Investigator Site 134 Jackson Mississippi 39216
Investigator Site 135 Las Vegas Nevada 89107
Investigator Site 118 Durham North Carolina 27710
Investigator Site #103 Cleveland Ohio 44106
Site Investigator #113 Toledo Ohio 43606
Investigator Site 101 Oklahoma City Oklahoma 73104
Investigator Site 136 Oklahoma City Oklahoma 73112
Investigator Site 106 Hershey Pennsylvania 17033
Investigator Site 111 Dallas Texas 75235
Investigator Site 116 Houston Texas 77030
Investigator Site 112 Richmond Virginia 23298

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03051490, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 7, 2018 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03051490 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →